Brian Rini, MD, FASCO
Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.
Articles by Brian Rini, MD, FASCO
Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field.
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
The panel talks about nonclear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
The panel shared their approach to treatment selection for clear cell kidney cancer.
Michael Morris, MD, discusses radioligand therapy for prostate cancer, including common practices and new data.
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
The panel discusses treatment options in the refractory RCC setting.
The panel discusses what is most exciting to them in the frontline RCC field.
The panel discusses toxicity management and use of precision medicine.
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.